CorrectSequence Therapeutics

CorrectSequence Therapeutics

Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

A gene therapy pioneer using CRISPR to develop curative treatments for genetic disorders.

Genetics & Genomics

Technology Platform

A gene editing platform utilizing CRISPR-based technologies to precisely correct disease-causing mutations in the genome.

Opportunities

Potential to create definitive, one-time cures for debilitating genetic diseases that currently have no effective treatments.

Risk Factors

Substantial risks related to off-target editing effects, immune responses, long-term safety, and challenging clinical development pathways.

Competitive Landscape

Competes in the high-stakes global gene editing field, requiring differentiation in editing efficiency, delivery, and intellectual property.